Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy of Clostridium Butyricum CBM588® on Symptoms and Quality of Life in Patients With Diarrhea-dominant Irritable Bowel Syndrome (PROREDI: (PRObiotic REmedy for DIarrhea)

NCT06676514 is registered in ClinicalTrials.gov with Liaquat University of Medical & Health Sciences as lead sponsor.

NCT NCT06676514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06676514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy of Clostridium Butyricum CBM588® on Symptoms and Quality of Life in Patients With Diarrhea-dominant Irritable Bowel Syndrome (PROREDI: (PRObiotic REmedy for DIarrhea)
Lead sponsor
Liaquat University of Medical & Health Sciences
Phase
Not applicable
Overall status
Completed
Start date
November 10, 2024
Completion date
March 10, 2025
Enrollment
405 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ibs-d (diarrhea-predominant)